Stockscreener 앱 받기
5.02
0.79%
-0.04
시간 외 거래:
5.12
0.10
+1.99%
전일 마감가:
$5.06
열려 있는:
$5.07
하루 거래량:
665.93K
Relative Volume:
0.44
시가총액:
$1.03B
수익:
-
순이익/손실:
$-118.84M
주가수익비율:
-9.3937
EPS:
-0.5344
순현금흐름:
$-101.06M
1주 성능:
-0.20%
1개월 성능:
-2.33%
6개월 성능:
+2.03%
1년 성능:
+71.33%
1일 변동 폭
$4.9924
$5.19
1주일 범위
$4.695
$5.20
52주 변동 폭
$1.89
$7.005
사바라 Stock (SVRA) Company Profile
명칭
Savara Inc
전화
51285113796
주소
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.02 | 1.04B | 0 | -118.84M | -101.06M | -0.5344 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
사바라 Stock (SVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 재개 | Oppenheimer | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-11-13 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 개시 | JMP Securities | Mkt Outperform |
| 2023-11-07 | 개시 | Guggenheim | Buy |
| 2023-05-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-03-16 | 개시 | Piper Sandler | Overweight |
| 2021-03-15 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-13 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 재개 | ROTH Capital | Neutral |
| 2018-01-03 | 개시 | Ladenburg Thalmann | Buy |
| 2017-09-27 | 재개 | ROTH Capital | Buy |
| 2017-09-22 | 개시 | Jefferies | Buy |
| 2017-09-11 | 개시 | JMP Securities | Mkt Outperform |
모두보기
사바라 주식(SVRA)의 최신 뉴스
Savara Inc. (SVRA) Reports Q1 Financial Results - Insider Monkey
Savara Inc stock (US80633A1025): fresh IMPALA?2 data at ATS 2026 keeps rare?disease bet in focus - AD HOC NEWS
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 20 - BioSpace
Savara presents biomarker data from molgramostim trial at ATS - Investing.com
Savara (SVRA) Reports New Clinical Findings at ATS 2026 Conferen - GuruFocus
Savara presents biomarker data from molgramostim trial at ATS By Investing.com - Investing.com Canada
Rare lung disease trial: Savara drug cuts biomarkers tied to severity - Stock Titan
SVRA Stock Price, Quote & Chart | SAVARA INC (NASDAQ:SVRA) - ChartMill
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - BioSpace
Savara presents 48-week data on molgramostim for rare lung disease - Investing.com Nigeria
48 weeks on Savara's aPAP drug show sustained lung and quality-of-life gains - Stock Titan
SVRA: MOLBREEVI nears approval for aPAP, backed by strong data and robust commercial preparation - TradingView
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - BioSpace
Savara Inc stock (US80633A1025): higher losses, trial progress and elevated short interest - AD HOC NEWS
Savara reports exercise improvements in aPAP drug trial By Investing.com - Investing.com Australia
Savara reports exercise improvements in aPAP drug trial - Investing.com
Is Savara’s Rising Quarterly Loss Reshaping the Risk‑Reward Profile for Investors in SVRA? - simplywall.st
Savara Inc stock (US80633A1025): respiratory disease specialist after latest clinical and funding up - AD HOC NEWS
SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy - Stocktwits
Guggenheim Reaffirms Their Buy Rating on Savara (SVRA) - The Globe and Mail
Savara stock (US80633A1025): Rare disease biotech gains 3.74% on trading momentum - AD HOC NEWS
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $16 - Moomoo
Savara Reports First Quarter Financial Results and Provides Business Update - BioSpace
SVRA SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Savara (SVRA) Prepares for Commercial Launch with Strong Financi - GuruFocus
SVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TradingKey - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Savara Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss - marketscreener.com
Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, Vs. FactSet Est of $-0.13 Loss - Moomoo
Savara Q1 net loss widens on higher R&D costs - TradingView
Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Savara (SVRA) deepens Q1 2026 loss while pushing MOLBREEVI toward key FDA and EMA decisions - Stock Titan
Potential first autoimmune PAP treatment faces Nov. 22 FDA decision - Stock Titan
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference - BioSpace
Swedbank AB Has $5.13 Million Position in Savara Inc. $SVRA - MarketBeat
Nan Fung Trinity HK Ltd. Takes $10.18 Million Position in Savara Inc. $SVRA - MarketBeat
Savara Inc. $SVRA Position Boosted by F m Investments LLC - MarketBeat
SVRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Number of shareholders of Savara, Inc. – NASDAQ:SVRA - TradingView
MSN Money - MSN
Savara faces earnings test ahead of crucial FDA decision By Investing.com - Investing.com South Africa
Savara faces earnings test ahead of crucial FDA decision - Investing.com
Savara (SVRA) to Release Earnings on Tuesday - MarketBeat
SVRA stock slips post-market after FDA delays decision on pulmonary therapy - MSN
Savara Grants Equity Awards to 24 New Employees - MyChesCo
US High Growth Tech Stocks To Watch - Sahm
Savara Inc. ticks higher amid takeover speculation - MSN
사바라 (SVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):